LOS ANGELES, Nov. 1, 2024 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against Edwards Lifesciences Corporation ("Edwards Lifesciences" or the "Company") (NYSE: EW).

Class Period: February 6, 2024 – July 24, 2024

Lead Plaintiff Deadline: December 13, 2024

If you wish to serve as lead plaintiff of the Edwards Lifesciences lawsuit, you can submit your contact information at www.glancylaw.com/cases/edwards-lifesciences-corporation/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

The complaint filed alleges that, throughout the Class Period, Defendants failed to disclose to investors that: (1) the Company did not possess reliable information pertaining to projected revenue outlook and anticipated growth; (2) the Company's growth was at risk of decelerating; (3) the Company's "patient activation activities" failed to reach the perceived low-treatment-rate population TAVR's growth relied upon obtaining; (4) the Company overstated hospital desire to continue to utilize the Company's TAVR procedures over newer, innovative structural heart therapies; and (5) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

Follow us for updates on LinkedIn, Twitter, or Facebook.

To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com.  If you inquire by email please include your mailing address, telephone number and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts 

Glancy Prongay & Murray LLP, Los Angeles

Charles Linehan, 310-201-9150 or 888-773-9224

shareholders@glancylaw.com

www.glancylaw.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/ew-investors-have-opportunity-to-lead-edwards-lifesciences-corporation-securities-fraud-lawsuit-302293677.html

SOURCE Glancy Prongay & Murray LLP